Open AccessThe 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies
Author(s) -
Benoît J. Arsenault,
S. Matthijs Boekholdt,
G. Kees Hovingh,
Craig Hyde,
David A. DeMicco,
Aurobindo Chatterjee,
Philip J. Barter,
Prakash Deedwania,
David D. Waters,
John C. LaRosa,
Terje R. Pedersen,
John J.P. Kastelein
Publication year - 2011
Publication title -
circulation cardiovascular genetics
Language(s) - English
Resource type - Journals
eISSN - 1942-325X
pISSN - 1942-3268
DOI - 10.1161/circgenetics.111.960252
Subject(s) - atorvastatin , hazard ratio , medicine , confidence interval , simvastatin , minor allele frequency , proportional hazards model , prospective cohort study , relative risk , statin , cardiology , gastroenterology , allele , biology , allele frequency , genetics , gene
Carriers of the KIF6 719Arg variant may be at increased risk for CVD and may benefit more from statin therapy, in terms of CVD risk reduction, than noncarriers. Our objective was to investigate whether carriers of the KIF6 719Arg genetic variant (rs20455) are at increased cardiovascular risk and obtain more benefit from high-dose statin therapy than do noncarriers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom